Physician profile
Vanesh Khetpal
NPI 1093946832
$8,403.95
in general payments reported to CMS, 2019-2025
28 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $30.34 · 2021: $1,199 · 2022: $1,970 · 2023: $2,128 · 2024: $1,802 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,137.35 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,037.00 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $864.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $779.46 | 2019-2025 | |
| Gilead Sciences, INC. | $740.20 | 2021-2025 | Veklury |
| Pfizer INC. | $553.63 | 2020-2025 | |
| Paratek Pharmaceuticals, INC. | $476.38 | 2021-2024 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.15 | 2019-2025 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $358.37 | 2022-2024 | Givlaari |
| Astrazeneca Pharmaceuticals Lp | $347.65 | 2019-2024 | Farxiga, Fasenra, Lokelma |
| Merck Sharp & Dohme LLC | $290.04 | 2021-2025 | Zerbaxa, Dificid, Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.68 | 2021-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $200.13 | 2021-2025 | Ultomiris |
| Boston Scientific Corporation | $196.26 | 2021-2025 | Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $127.80 | 2019-2024 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $125.74 | 2021-2022 | |
| Scpharmaceuticals INC. | $112.01 | 2024-2025 | |
| Melinta Therapeutics, LLC | $75.55 | 2021-2022 | |
| Inari Medical, INC. | $64.98 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Electromed, INC. | $60.62 | 2022-2024 | Smartvest |
| Kestra Medical Technology Services, INC. | $38.29 | 2023-2024 | Assure Wcd |
| Sunovion Pharmaceuticals INC. | $24.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.79 | 2019 | |
| Abbott Laboratories | $23.78 | 2024 | Freestyle Libre 3 |
| Bioxcel Therapeutics, INC. | $17.03 | 2023 | Igalmi |
| Alkermes, INC. | $16.07 | 2019 | |
| Glaxosmithkline, LLC. | $15.77 | 2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanesh Khetpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.